| DSCLX | VTIAX | DSCLX / VTIAX | |
| Total Expense Ratio | 0.26 | 0.09 | 289% |
| Annual Report Gross Expense Ratio | 0.26 | 0.09 | 289% |
| Fund Existence | 14 years | 16 years | - |
| Gain YTD | 10.754 | 14.651 | 73% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 3000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.23B | 629B | 0% |
| Annual Yield % from dividends | 3.04 | 2.63 | 116% |
| Returns for 1 year | 27.26 | 29.03 | 94% |
| Returns for 3 years | 74.73 | 59.48 | 126% |
| Returns for 5 years | 51.77 | 35.27 | 147% |
| Returns for 10 years | 123.95 | 104.40 | 119% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XJH | 50.75 | 0.36 | +0.71% |
| iShares ESG Select Scrn S&P Mid-Cap ETF | |||
| OUNZ | 43.15 | 0.08 | +0.19% |
| VanEck Merk Gold Trust | |||
| VLT | 10.49 | 0.01 | +0.14% |
| Invesco High Income Trust II | |||
| CAIQ | 27.00 | -0.03 | -0.09% |
| Calamos Nasdaq Autocallable Income ETF | |||
| LFSC | 37.61 | -1.01 | -2.62% |
| F/m Emerald Life Sciences Innovation ETF | |||